Lancet Oncol. 21, 508–518 (2020)

Matching people with pancreatic cancer to relevant molecularly guided treatments increases the overall survival of patients relative to that of those without actionable mutations or those who do not receive targeted therapy.

One of the goals of characterizing cancer mutations is to identify therapies that target those mutations and reduce cancer growth. However, there are limited real-world examples of the benefits of this.

The Know Your Tumor program recruited 1,856 US patients with pancreatic cancer; within this cohort, 46 had actionable mutations and were given relevant tailored therapies. Their median survival was significantly longer than that of both those with actionable mutations who were not given tailored therapies and those without actionable mutations. These real-world data suggest promise for this personalized approach.